Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)

v3.22.2.2
Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)
1 Months Ended 3 Months Ended 9 Months Ended
Jan. 31, 2010
contingent_value_right
Sep. 30, 2022
USD ($)
Sep. 30, 2022
USD ($)
Dec. 31, 2021
USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Number of CVR Series | contingent_value_right 4      
Transferred over Time | Phase 3 Clinical Trial        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Gross contract asset   $ 10,000,000 $ 10,000,000  
Maximum | Transferred over Time | Development, Regulatory, & Commercial Milestones and Tiered Royalties        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Investments   375,000,000 375,000,000  
Metabasis        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Number of CVRs issued per acquiree share | contingent_value_right 4      
Number of CVRs issued from each CVR series | contingent_value_right 1      
Frequency of cash payments to CVR holders 6 months      
Mark-to-market adjustment of CVR liability   100,000 (900,000)  
Icagen        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Mark-to-market adjustment of CVR liability   (200,000) (500,000)  
Payment for contingent consideration liabilities     1,500,000  
xCella        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Payment for contingent consideration liabilities   1,000,000 1,000,000  
xCella | Earnout Rights for Partner Research and Development        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Earnout rights recognized   500,000 1,400,000  
Recurring        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Total assets   117,291,000 117,291,000 $ 321,586,000
Amounts owed to former licensor   73,000 73,000 86,000
Total liabilities   8,701,000 8,701,000 11,157,000
Recurring | Short-term investments        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Investments, fair value   99,026,000 99,026,000 290,697,000
Recurring | Common Stock        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Investments, fair value   18,265,000 18,265,000 30,889,000
Recurring | Contingent Liabilities | CyDex        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Contingent liabilities   308,000 308,000 349,000
Recurring | Contingent Liabilities | Metabasis        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Contingent liabilities   2,507,000 2,507,000 3,358,000
Recurring | Contingent Liabilities | Icagen        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Contingent liabilities   5,333,000 5,333,000 7,364,000
Recurring | Contingent Liabilities | xCella        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Contingent liabilities   480,000 480,000 0
Recurring | Level 1        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Total assets   22,914,000 22,914,000 40,624,000
Amounts owed to former licensor   73,000 73,000 86,000
Total liabilities   73,000 73,000 86,000
Recurring | Level 1 | Short-term investments        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Investments, fair value   4,649,000 4,649,000 9,735,000
Recurring | Level 1 | Common Stock        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Investments, fair value       30,889,000
Recurring | Level 1 | Contingent Liabilities | CyDex        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Contingent liabilities   0 0 0
Recurring | Level 1 | Contingent Liabilities | Metabasis        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Contingent liabilities   0 0 0
Recurring | Level 1 | Contingent Liabilities | Icagen        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Contingent liabilities   0 0 0
Recurring | Level 1 | Contingent Liabilities | xCella        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Contingent liabilities   0 0 0
Recurring | Level 2        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Total assets   94,145,000 94,145,000 280,553,000
Amounts owed to former licensor   0 0 0
Total liabilities   2,507,000 2,507,000 3,358,000
Recurring | Level 2 | Short-term investments        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Investments, fair value   94,145,000 94,145,000 280,553,000
Recurring | Level 2 | Common Stock        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Investments, fair value   0 0 0
Recurring | Level 2 | Contingent Liabilities | CyDex        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Contingent liabilities   0 0 0
Recurring | Level 2 | Contingent Liabilities | Metabasis        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Contingent liabilities   2,507,000 2,507,000 3,358,000
Recurring | Level 2 | Contingent Liabilities | Icagen        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Contingent liabilities   0 0 0
Recurring | Level 2 | Contingent Liabilities | xCella        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Contingent liabilities   0 0 0
Recurring | Level 3        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Total assets   232,000 232,000 409,000
Amounts owed to former licensor   0 0 0
Total liabilities   6,121,000 6,121,000 7,713,000
Recurring | Level 3 | Short-term investments        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Investments, fair value   232,000 232,000 409,000
Recurring | Level 3 | Common Stock        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Investments, fair value   0 0 0
Recurring | Level 3 | Contingent Liabilities | CyDex        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Contingent liabilities   308,000 308,000 349,000
Recurring | Level 3 | Contingent Liabilities | Metabasis        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Contingent liabilities   0 0 0
Recurring | Level 3 | Contingent Liabilities | Icagen        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Contingent liabilities   5,333,000 5,333,000 7,364,000
Recurring | Level 3 | Contingent Liabilities | xCella        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Contingent liabilities   $ 480,000 $ 480,000 $ 0